Suivre
Abonner Abbott Laboratories

Abbott Laboratories

Filtre
  • 09.03.2010 – 22:55

    Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech

    ABBOTT PARK, Illinois and REDWOOD CITY, California, March 9, 2010 (ots/PRNewswire) -- Abbott and Facet Biotech Corporation announced today a definitive agreement for Abbott to acquire Facet, enhancing Abbott's early- and mid-stage pharmaceutical pipeline. Abbott will acquire Facet for US$27 per share in cash for a net transaction value of approximately US$450 ...

  • 02.03.2010 – 13:32

    Twenty-Five Years of HIV Blood Testing Helped to Positively Transform Global Health Crisis

    Abbott Park, Illinois, March 2, 2010 (ots/PRNewswire) - Imagine delaying a life-saving surgery or being afraid to receive or donate blood for fear of contracting HIV (http://www.who.int/hiv/en/). It seems unbelievable today, but twenty-five years ago, this was the reality as the world struggled to keep the deadly virus out of the blood supply. (Photo: ...

  • 16.02.2010 – 07:31

    Abbott Completes Acquisition of Solvay Pharmaceuticals

    Abbott Park, Illinois, February 16, 2010 (ots/PRNewswire) - Abbott today announced that it has completed its EUR 4.5 billion (US$6.2 billion) acquisition of Belgium-based Solvay Pharmaceuticals, providing Abbott with a large and complementary portfolio of pharmaceutical products and expanding Abbott's presence in key global emerging markets. Based on the timing of the close, Abbott expects the acquisition to add ...

  • 21.01.2010 – 21:55

    Abbott to Suspend Marketing of Obesity Medicine Sibutramine in European Union Countries

    Abbott Park, Illinois (ots/PRNewswire) - Today the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) voted to recommend the suspension of marketing authorizations for all anti-obesity medicines containing sibutramine. Abbott will comply with the CHMP recommendation and suspend the marketing of Abbott medicines containing ...

  • 14.01.2010 – 15:31

    Abbott Receives European Regulatory Approval for New Ovarian Cancer Diagnostic Test

    Abbott Park, Illinois (ots/PRNewswire) - A new diagnostic tool, which studies show can aid in determining the risk of whether a pelvic mass is benign or malignant, is now available in Europe. This simple blood test is expected to help in the assessment of epithelial ovarian cancer, the most lethal form of gynecological cancer. This important immunoassay, which will ...

  • 06.01.2010 – 20:27

    New Abbott Gene-Based Test for Colorectal Cancer Receives CE Mark

    Des Plaines, Illinois (ots/PRNewswire) - Abbott announced today it has received CE Marking (Conformite Europeene) in the European Union for a new molecular diagnostic test, Abbott RealTime mS9 Colorectal Cancer, a non-invasive DNA assay that detects the methylated form of Septin 9, a gene linked to colorectal cancer, in blood specimens. The product is not available for sale in the United States. The RealTime mS9 ...